165 related articles for article (PubMed ID: 21829534)
1. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
[TBL] [Abstract][Full Text] [Related]
2. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
4. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
[TBL] [Abstract][Full Text] [Related]
5. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg.
Ayyoub M; Pignon P; Classe JM; Odunsi K; Valmori D
Cancer Immunol Res; 2013 Nov; 1(5):303-8. PubMed ID: 24777968
[TBL] [Abstract][Full Text] [Related]
7. Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.
Isobe M; Eikawa S; Uenaka A; Nakamura Y; Kanda T; Kohno S; Kuzushima K; Nakayama E
Cancer Immun; 2009 Oct; 9():8. PubMed ID: 19791734
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
9. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
10. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
Nishikawa H; Jäger E; Ritter G; Old LJ; Gnjatic S
Blood; 2005 Aug; 106(3):1008-11. PubMed ID: 15840697
[TBL] [Abstract][Full Text] [Related]
11. CD4
Wei Y; Yu K; Wei H; Su X; Zhu R; Shi H; Sun H; Luo Q; Xu W; Xiao J; Zhong Y; Zeng Q
Immunology; 2017 Jul; 151(3):291-303. PubMed ID: 28207945
[TBL] [Abstract][Full Text] [Related]
12. Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.
Nishikawa H; Tsuji T; Jäger E; Briones G; Ritter G; Old LJ; Galán JE; Shiku H; Gnjatic S
Blood; 2008 Feb; 111(3):1404-12. PubMed ID: 17986662
[TBL] [Abstract][Full Text] [Related]
13. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
Hirayama M; Nishikawa H; Nagata Y; Tsuji T; Kato T; Kageyama S; Ueda S; Sugiyama D; Hori S; Sakaguchi S; Ritter G; Old LJ; Gnjatic S; Shiku H
Eur J Immunol; 2013 Apr; 43(4):989-1000. PubMed ID: 23436617
[TBL] [Abstract][Full Text] [Related]
14. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
[TBL] [Abstract][Full Text] [Related]
15. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.
Nishikawa H; Qian F; Tsuji T; Ritter G; Old LJ; Gnjatic S; Odunsi K
J Immunol; 2006 May; 176(10):6340-6. PubMed ID: 16670346
[TBL] [Abstract][Full Text] [Related]
16. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia.
Santner-Nanan B; Peek MJ; Khanam R; Richarts L; Zhu E; Fazekas de St Groth B; Nanan R
J Immunol; 2009 Dec; 183(11):7023-30. PubMed ID: 19915051
[TBL] [Abstract][Full Text] [Related]
17. IL-2 contributes to maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required for immune control of blood-stage malaria infection.
Berretta F; St-Pierre J; Piccirillo CA; Stevenson MM
J Immunol; 2011 Apr; 186(8):4862-71. PubMed ID: 21389253
[TBL] [Abstract][Full Text] [Related]
18. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
19. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.
Mizote Y; Uenaka A; Isobe M; Wada H; Kakimi K; Saika T; Kita S; Koide Y; Oka M; Nakayama E
Vaccine; 2014 Feb; 32(8):957-64. PubMed ID: 24397899
[TBL] [Abstract][Full Text] [Related]
20. Cord blood derived CD4+ CD25(high) T cells become functional regulatory T cells upon antigen encounter.
Mayer E; Bannert C; Gruber S; Klunker S; Spittler A; Akdis CA; Szépfalusi Z; Eiwegger T
PLoS One; 2012; 7(1):e29355. PubMed ID: 22272233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
